Immuron Q3 Sales reach 150% of 1H Sales

Rhea-AI Summary

Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported robust sales results for Q3 FY23, highlighting a significant turnaround in demand for its gastrointestinal products, Travelan® and Protectyn®.

Sales soared to A$1.46 million year-to-date, reflecting a 239% increase from A$430k in the same period last year. In Australia, Q3 FY23 sales reached A$577k, representing 201% of first-half sales. North American sales mirrored this trend, with Q3 reaching A$298k, equating to 100% of first-half sales.

This growth is attributed to a rebound in overseas travel and increasing sales through clinics and distributors, emphasizing the company’s strategy to restock and build inventory. Immuron remains committed to expanding its product portfolio and driving sales growth.

Positive

• Q3 FY23 global sales increased by 239% to A$1.46M compared to A$430k in FY22.
• Australian Q3 FY23 sales reached A$577k, representing 201% of 1H FY23 sales.
• North American Q3 FY23 Travelan® sales of A$298k equate to 100% of 1H FY23 sales and a 70% increase over FY22.
• Sales growth attributed to a rebound in overseas travel and strong distributions through clinics.

Negative

• Sales not yet at pre-pandemic levels despite growth.

Highlights:

• Australian Q3 FY23 sales of A$577 k (201% of 1H sales)
• North American Q3 FY23 Travelan^® sales of A$298 k (100% of 1H sales)
• Global Q3 YTD FY23 sales of A$1.46 M represent an increase of 239% compared with the corresponding period in FY22 of A$430 k
  

MELBOURNE, Australia, April 06, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce the Q3 FY23 sales* results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan^® and Protectyn^®.

Global Q3 YTD sales of Travelan^® and Protectyn^® increased by 239% in FY23 to AUD $1.46 M, compared to AUD $430 k for the corresponding period in FY22.

In Australia, Travelan^® and Protectyn^® sales for Q3 were AUD $577 k, a 101% increase on sales for 1H FY23 (AUD $287 k). Australian Travelan^® and Protectyn^® Q3 YTD FY23 sales were AUD $864 k representing a significant increase over the corresponding period in FY22 (AUD $80k). Travelan^® sales increase as overseas travel rebounds. Australian resident short term departures in January 2023 were 80% of those in January 2019 (Australian Bureau of Statistics). Immuron continues to restock wholesalers in line with increasing pharmacy sales.

North American Travelan^® Q3 FY23 sales were AUD $298 k, greater than sales for 1H FY23 (AUD $297 k). North American Travelan^® Q3 YTD FY23 sales were AUD $595 k, up by 70% on the corresponding period in FY22 (AUD $350 k). This growth was attributable to increasing sales in both Passport Health Travel Clinics and distributor sales. While not at pre-pandemic peak, sales in the US are anticipated to increase as Immuron replenishes and builds inventory.

Immuron is focused on growing sales of its commercial products, expanding its portfolio of products and has a strong existing pipeline.

*Unaudited

COMPANY CONTACT: Steven Lydeamore Chief Executive Officer Ph: +61 (0)3 9824 5254 info@immuron.com

About Travelan^®

Travelan^® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan^® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan^® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan^® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan^® is sold as a dietary supplement for digestive tract protection.

About Travelers’ diarrhea

Travelers’ diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with travelers’ diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information visit: http://www.immuron.com

FAQ

What were the Q3 FY23 sales results for Immuron (IMRN)?

Immuron reported global Q3 FY23 sales of A$1.46 million, a 239% increase compared to A$430k in FY22.

How did Australian sales perform in Q3 FY23 for Immuron's products?

Australian sales for Q3 FY23 totaled A$577k, which is 201% of the sales in the first half of FY23.

What were the North American sales figures for Travelan® in Q3 FY23?

North American Travelan® sales reached A$298k in Q3 FY23, matching the total for the first half of FY23.

What factors contributed to the increase in Immuron's sales?

The sales increase was driven by a rebound in overseas travel and enhanced distribution through clinics and distributors.